Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonist-based therapies (GLP) may offer protective effects against severe long-term consequences of COVID-19.
- GLP therapies are associated with weight loss.
- These medications may exert antihyperglycemic effects, helping to regulate blood sugar levels.
- GLP therapies could have anti-inflammatory effects, potentially reducing inflammation in the body.
- There is evidence suggesting cardiovascular and endothelial protection from GLP therapies.
Simplified